Getting closer and closer to our needs...
"Today we are extremely pleased to announce that the Myelin Repair Foundation
has achieved its goal of a myelin repair Phase 1 clinical trial for multiple
sclerosis three years earlier than expected.
This achievement illustrates the effectiveness of our innovative Accelerated
Research Collaboration (ARC) Model to advance research forward, moving closer
to the development of a myelin repair therapeutic for MS patients. However,
even with this incredible success, it is paramount we continue to aggressively
push research forward into multiple clinical trials, giving us the best chance
of developing an effective myelin repair drug as rapidly as possible.
With our support, MRF Principal Investigator Dr. Robert Miller at Case Western
Reserve University's research has now entered into a Phase 1 clinical trial.
This trial is being conducted at Cleveland Clinic, examining the efficacy of a
new myelin repair therapeutic pathway with mesenchymal stem cells (MSCs).
For more information on the clinical trial and other multiple sclerosis trials
in progress, please visit www.clinicaltrials.gov.
As momentous as this milestone is for all of us at MRF and MS patients
worldwide, this achievement would not be possible without your generosity. Now
more than ever, we need your support to continue to optimize our success. Thank
you.
You may read the full clinical trial press release here, or learn more about
MRF's recent research breakthroughs by visiting our website at
www.myelinrepair.org.
Best regards,
Myelin Repair Foundation Staff"
